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Purpose of the study
To assess statistical agreement of metabolic syndrome
(MS) ATPIII, IDF, EGIR and AACE classification in HIV-
infected patients and association with body fat redistribu-
tion.
Methods
Cross-sectional observational study that included all con-
secutive HIV-infected patients seen at a metabolic clinic
who were screened for MS and had a clinical and radiolog-
ical lipodystrophy (LD) evaluation. Cohen's Kappa statis-
tic was calculated to assess statistical agreement between
different MS classifications. Logistic regression models
were performed to identify factors associated with differ-
ent MS classifications. (Tables 1 and 2.)
Summary of results
1,348 pts were included in the analysis.
Figure 1 depicts prevalence of metabolic syndrome
according to different definition.
Conclusion
Concordance between MS classification is less than ideal.
After adjusting for BMI strata, lipodystrophy phenotypes
and central fat accumulation are associated with for MS
diagnosis.
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Table 1: K of Cohen shows a low level of agreement between MS 
classifications.
EGIR AACE NCEP ATP-III
IDF 0.27* (64.61%) 0.07* (56.01%) 0.41* (71.66%)
EGIR 0.21* (74.33%) 0.38* (75.74%)
AACE 0.35* (81.68%)
*p-value < 0.001 Body fat changes (LD definition and objective 
anthropometric variables) were included in univariable and 
multivariable logistic analysis.
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Table 2: 
Variables ATP-III Adj. OR (95% CI) P-value EGIR Adj. OR (95% CI) P-value IDF Adj. OR (95% CI) P-value
Lipoatrophy 1.14 (0.66; 1.96) 0.63 1.20 (0.71; 2.03) 0.49 1.21 (0.79; 1.84) 0.37
Central adiposity 1.87 (0.99; 3.53) 0.054 2.88 (1.64; 4.27) 0.001 2.14 (1.21; 3.79) 0.009
Mixed form 2.06 (1.26; 3.37) 0.004 2.65 (1.64; 4.27) <0.0001 2.12 (1.43; 3.14) <0.0001
% fat legs (10%) 1.04 (0.82; 1.32) 0.73 0.73 (0.57; 0.93) 0.013 0.91 (0.74; 1.13) 0.41
VAT/TAT 12.35 (4.84; 31.48) <0.0001 2.80 (1.16; 6.78) 0.022 2.37 (1.08; 5.21) 0.031
BMI
<19 0.33 (0.13; 0.86) 0.024 0.30 (0.12; 0.78) 0.014 0.51 (0.28; 0.92) 0.027
between 19 and 25 Ref. - Ref. - Ref. -
between 25 and 30 2.12 (1.51; 2.99) <0.0001 2.36 (1.70; 3.28) <0.0001 2.42 (1.76; 3.32) <0.0001
>30 5.56 (3.04; 10.16) <0.0001 12.38 (6.28; 24.43) <0.0001 5.99 (3.02; 11.90) <0.0001
Figure 1
